Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (23119)	7/13/1998 1:25:00 PM
From: WTDEC	Read Replies (2) \| Respond to of 32384

Henry, you have been pretty much on the mark in seeing the business side of LGND unfold. Your input is much appreciated. The constant beat of a successful company will even be heard on Wall Street . . . .eventally :-) Regards, Walter

To: Henry Niman who wrote (23119)	7/13/1998 1:48:00 PM
From: Robert L. Ray	Read Replies (1) \| Respond to of 32384

>>>KS still affects a significant number of people and off label use could be significant. <<< What off label uses do you suspect might have the greatest potential? Understand I'm not asking you to name an indication solely because it would have a high dollar value but please name off label indication/s that Panretin realistically has a good chance of being effective for? Thanks. Sure would like to see this thing hold on to it's gain today and not sell off at the close.